These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264 [TBL] [Abstract][Full Text] [Related]
6. Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model. Briand F; Brousseau E; Quinsat M; Burcelin R; Sulpice T Eur J Pharmacol; 2018 Jan; 818():449-456. PubMed ID: 29155143 [TBL] [Abstract][Full Text] [Related]
8. CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients. Pockros PJ; Fuchs M; Freilich B; Schiff E; Kohli A; Lawitz EJ; Hellstern PA; Owens-Grillo J; Van Biene C; Shringarpure R; MacConell L; Shapiro D; Cohen DE Liver Int; 2019 Nov; 39(11):2082-2093. PubMed ID: 31402538 [TBL] [Abstract][Full Text] [Related]
9. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice. Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284 [TBL] [Abstract][Full Text] [Related]
10. Obeticholic acid-a new therapy in PBC and NASH. Chapman RW; Lynch KD Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030 [TBL] [Abstract][Full Text] [Related]
11. Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH. Loomba R; Neuschwander-Tetri BA; Sanyal A; Chalasani N; Diehl AM; Terrault N; Kowdley K; Dasarathy S; Kleiner D; Behling C; Lavine J; Van Natta M; Middleton M; Tonascia J; Sirlin C; Hepatology; 2020 Oct; 72(4):1219-1229. PubMed ID: 31965579 [TBL] [Abstract][Full Text] [Related]
12. The effect and safety of obeticholic acid for patients with nonalcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials. Zhao J; Li B; Zhang K; Zhu Z Medicine (Baltimore); 2024 Feb; 103(7):e37271. PubMed ID: 38363900 [TBL] [Abstract][Full Text] [Related]
14. REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. Ratziu V; Sanyal AJ; Loomba R; Rinella M; Harrison S; Anstee QM; Goodman Z; Bedossa P; MacConell L; Shringarpure R; Shah A; Younossi Z Contemp Clin Trials; 2019 Sep; 84():105803. PubMed ID: 31260793 [TBL] [Abstract][Full Text] [Related]
15. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. Kowdley KV; Vuppalanchi R; Levy C; Floreani A; Andreone P; LaRusso NF; Shrestha R; Trotter J; Goldberg D; Rushbrook S; Hirschfield GM; Schiano T; Jin Y; Pencek R; MacConell L; Shapiro D; Bowlus CL; J Hepatol; 2020 Jul; 73(1):94-101. PubMed ID: 32165251 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Hirschfield GM; Mason A; Luketic V; Lindor K; Gordon SC; Mayo M; Kowdley KV; Vincent C; Bodhenheimer HC; Parés A; Trauner M; Marschall HU; Adorini L; Sciacca C; Beecher-Jones T; Castelloe E; Böhm O; Shapiro D Gastroenterology; 2015 Apr; 148(4):751-61.e8. PubMed ID: 25500425 [TBL] [Abstract][Full Text] [Related]
17. Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis. Adorini L; Rigbolt K; Feigh M; Roth J; Erickson M PLoS One; 2024; 19(4):e0300809. PubMed ID: 38662778 [TBL] [Abstract][Full Text] [Related]
18. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204 [TBL] [Abstract][Full Text] [Related]
19. Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis. Chalasani N; Abdelmalek MF; Loomba R; Kowdley KV; McCullough AJ; Dasarathy S; Neuschwander-Tetri BA; Terrault N; Ferguson B; Shringarpure R; Shapiro D; Sanyal AJ Liver Int; 2019 May; 39(5):924-932. PubMed ID: 30253043 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of obeticholic acid in liver disease-A systematic review and meta-analysis. Kulkarni AV; Tevethia HV; Arab JP; Candia R; Premkumar M; Kumar P; Sharma M; Reddy DN; Padaki NR Clin Res Hepatol Gastroenterol; 2021 May; 45(3):101675. PubMed ID: 33722778 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]